WUXIF - Week In Review: Adiso Breaks Out Of Stealth With $95 Million From Morningside
- Concord, Mass.-based Adiso Therapeutics, an anti-inflammatory biotech, officially emerged from stealth mode with backing from Hong Kong's Morningside Ventures. Morningside has already invested $60 million in the company and has another $35 million earmarked for the company's B round.
- Microbiotica, a UK microbiome drug company, completed a $67 million B Financing co-led by China's Tencent and Flerie Invest, a Swedish life science investor.
- Shanghai Nuance Pharma acquired China rights to a drug-free nasal spray, Bentrio, developed by Switzerland's Altamira Therapeutics in a $23.5 million agreement.
- TheSEC warned three China biopharmas - Beigene, Zai Lab and Hutchmed - that theirUS-listed ADRs face delisting in three years' time.
For further details see:
Week In Review: Adiso Breaks Out Of Stealth With $95 Million From Morningside